These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related]
4. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Barnett AH Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665 [TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Diamant M; Heine RJ Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962 [TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Defronzo RA; Mehta RJ; Schnure JJ Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744 [TBL] [Abstract][Full Text] [Related]
7. PPAR-γ agonism for cardiovascular and renal protection. Sarafidis PA; Georgianos PI; Lasaridis AN Cardiovasc Ther; 2011 Dec; 29(6):377-84. PubMed ID: 20840193 [TBL] [Abstract][Full Text] [Related]
8. [Cardiovascular effects of rosiglitazone]. Le Feuvre C Presse Med; 2004 Jun; 33(11):735-45. PubMed ID: 15257231 [TBL] [Abstract][Full Text] [Related]
9. New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. Braunstein S Clin Ther; 2003 Jul; 25(7):1895-917. PubMed ID: 12946541 [TBL] [Abstract][Full Text] [Related]
10. [Heart failure with thiazolidinedione treatment: what do we know today?]. Erdmann E Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858 [TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
12. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Meriden T Clin Ther; 2004 Feb; 26(2):177-90. PubMed ID: 15038941 [TBL] [Abstract][Full Text] [Related]
14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
15. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. Molavi B; Rassouli N; Bagwe S; Rasouli N Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815 [TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Stolar MW; Chilton RJ Clin Ther; 2003; 25 Suppl B():B4-31. PubMed ID: 14553864 [TBL] [Abstract][Full Text] [Related]
17. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Seufert J; Lübben G; Dietrich K; Bates PC Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452 [TBL] [Abstract][Full Text] [Related]
18. Thiazolidinedione derivatives in type 2 diabetes mellitus. Tack CJ; Smits P Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214 [TBL] [Abstract][Full Text] [Related]
19. Effects of the thiazolidinediones on cardiovascular risk factors. Gilling L; Suwattee P; DeSouza C; Asnani S; Fonseca V Am J Cardiovasc Drugs; 2002; 2(3):149-56. PubMed ID: 14727977 [TBL] [Abstract][Full Text] [Related]
20. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control. Seufert J Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]